Business Wire - September 10, 2009
RESEARCH TRIANGLE PARK, N.C. - Quintiles, the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide, today announced a strategic alliance agreement with the University of Pretoria as part of its industry unique Prime Site program, an initiative to accelerate the development of new and more effective medicines. The University of Pretoria is the third location in the Quintiles Prime Site program which already includes Queen Mary's College in London and the Washington Hospital Center in Washington DC.
"Prime Sites are large clinical institutions that collaborate with Quintiles to enhance their infrastructure for conducting clinical trials." Explained Dr Christopher Cabell, Head of Global Access to Patients. "The University of Pretoria was selected because of its experience in conducting clinical research, its access to substantial patient populations and clinical expertise all across multiple therapeutic areas. Through this new partnership Quintiles will be able to significantly improve its ability to access patients and investigators who are critical to facilitating the increasingly complex therapies under development."
Gillian Corken, Quintiles, Africa, said: "The addition of University of Pretoria to the Prime Site program is a key milestone for Quintiles and also for us in South Africa as it recognizes the quality of our clinical research. Taking some key learnings from both Queen Mary's College and the Washington Hospital Center, and with the enthusiasm and vision for this unprecedented model that our University of Pretoria partners have shown, we have confidence in being able to accelerate the initiation of this site. By consolidating research in areas of high patient and investigator density we can dramatically improve efficiencies particularly in feasibility and recruitment."
Professor Robin Crewe, University of Pretoria, said: "We take enormous pride in being recognized nationally and internationally as an outstanding institution for research and clinical service and we have committed significant management resource to ensuring that we can fully realize the potential of this alliance. By becoming part of Quintiles' Prime Site program we will not only benefit from greater efficiencies in monitoring and contracting, but we will also be able to provide pools of patients for Quintiles' entire pipeline of high-quality studies. Moreover, we regard this as an outstanding opportunity for elevating the profile of our clinical research work to new audiences."
The Prime Site program is already yielding impressive results in its established locations at Queen Mary's College in London, UK and the Washington Hospital Centre in Washington, USA. Across both current Prime Site locations, seven new studies have begun in 2009 to date with a further six already scheduled for later in the year. Accordingly, Quintiles has been testing twenty eight different drugs across both sites in 2009, and shall look to continue to build on these successes at the University of Pretoria site. Key to the success of the program so far is Quintiles efforts to harmonize operational processes, drive efficiencies in start-up and build better relationships with site staff, which, in turn, supports patient recruitment.
Quintiles strategic vision is to set up numerous Prime Sites around the world, building on the success that it has already seen, and moving to include emerging markets in Asia, Latin America and Central & Eastern Europe in the program.
The announcement of this agreement with the University of Pretoria comes after the opening of a Quintiles office in Ghana to improve efficiency and expand capacity to monitor the growing number of clinical studies being conducted in Western Sub-Saharan Africa, particularly for diseases such as Malaria, HIV and Tuberculosis.
About Quintiles:
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. The Quintiles network of 23,000 engaged professionals in more than 50 countries around the globe works with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies navigate risk and seize opportunities in an environment where change is constant. For more information, please visit www.quintiles.com.
Contacts
Quintiles
Charlotte Taylor, Media Relations
media.info@quintiles.com
+441344 708 386
or
Greg Connors, Investor Relations
invest@quintiles.com
+1 919 998 2000
090910
BW090916
Copyright © 2009 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .